A South Africa guide to checking peptide offers against SAHPRA's current public warning, registered-medicine directory, and licensed-establishment records.
SAHPRA currently names several peptides promoted through online platforms, social media, gyms, wellness centres, and informal suppliers. A product name, research label, local address, or laboratory report cannot replace the exact medicine and establishment records.
Use this checklist to verify the local product, seller, and supply records before comparing price or availability.
Start with SAHPRA's public peptide page, which specifically addresses BPC-157, TB-500, CJC-1295, ipamorelin, PT-141, AOD-9604, Selank, Semax, Melanotan II, and certain GLP-1 products.
Use SAHPRA's Medicines Online Directory and registered-health-product resources to match the exact medicine, active ingredient, holder, pack, and current information instead of relying on a shared peptide name.
Check SAHPRA's pharmaceutical establishment register for the named manufacturer, importer, wholesaler, or distributor. A product entry and an establishment licence answer separate questions.
Each answer is tied to the local records below so you can see what is confirmed, what remains unknown, and where to recheck it. Open the primary sources ↓
No blanket answer is supportable. Start with SAHPRA's public peptide page, which specifically addresses BPC-157, TB-500, CJC-1295, ipamorelin, PT-141, AOD-9604, Selank, Semax, Melanotan II, and certain GLP-1 products. In South Africa, begin with Medicines Online Directory from South African Health Products Regulatory Authority; the product, seller, and supply route still need to resolve to the same current record.
No. Peptide Local withholds a commercial table for South Africa until seller category, local delivery, regulatory or research status, exact price, and observation date are all sourced. This page is a verification route, not a shopping recommendation.
For South Africa, start with Medicines Online Directory from South African Health Products Regulatory Authority, then open Pharmaceutical establishment licensing from South African Health Products Regulatory Authority. The records answer separate questions, so confirm each current entry instead of treating one match as proof of the seller, product, and route together.
Resolve the identity first, then use this country’s official product and seller records. A matching name never transfers approval, trial evidence, or seller authority.
KPV is tracked as an unapproved tripeptide identity with preclinical and laboratory evidence. FDA states that neither KPV free base nor KPV acetate is a component of an FDA-approved drug and that it found no published study in which a KPV drug product was administered to humans. A seller listing, formulation, or research label cannot establish clinical benefit, safety, local authorization, or lawful supply.
Primary identity sourceFDA briefing document for KPV-related bulk drug substancesU.S. Food and Drug Administration ↗BPC-157 is tracked as a US research-market identity, not as an authorization or local supply finding for South Africa. Match the exact category, legal seller identity, and claimed route against the official records on this page.
Primary identity sourceRead the FDA sourceU.S. Food and Drug Administration ↗SAHPRA names TB-500 among peptide products unlawfully marketed in South Africa and states that products intended to treat, prevent, or alter bodily functions must be registered before sale. That guidance does not authenticate a specific online listing or seller.
Primary identity sourceRead the FDA sourceU.S. Food and Drug Administration ↗GHK-Cu is tracked as a US research-market identity, not as an authorization or local supply finding for South Africa. Match the exact category, legal seller identity, and claimed route against the official records on this page.
Primary identity sourceRead the PubChem compound recordNational Library of Medicine, PubChem ↗SAHPRA names Semax among peptide products unlawfully marketed in South Africa and states that products intended to treat, prevent, or alter bodily functions must be registered before sale. That guidance does not authenticate a specific online listing or seller.
Primary identity sourceRead the FDA sourceU.S. Food and Drug Administration ↗SAHPRA names Melanotan II among peptide products unlawfully marketed in South Africa and states that products intended to treat, prevent, or alter bodily functions must be registered before sale. That guidance does not authenticate a specific online listing or seller.
Primary identity sourceRead the FDA sourceU.S. Food and Drug Administration ↗MOTS-c is tracked as a US research-market identity, not as an authorization or local supply finding for South Africa. Match the exact category, legal seller identity, and claimed route against the official records on this page.
Primary identity sourceRead the FDA sourceU.S. Food and Drug Administration ↗Tesamorelin is tracked as a US research-market identity, not as an authorization or local supply finding for South Africa. Match the exact category, legal seller identity, and claimed route against the official records on this page.
Primary identity sourceCheck the FDA Purple Book product recordU.S. Food and Drug Administration ↗SAHPRA names AOD-9604 among peptide products unlawfully marketed in South Africa and states that products intended to treat, prevent, or alter bodily functions must be registered before sale. That guidance does not authenticate a specific online listing or seller.
Primary identity sourceRead the FDA sourceU.S. Food and Drug Administration ↗SAHPRA names ipamorelin among peptide products unlawfully marketed in South Africa and states that products intended to treat, prevent, or alter bodily functions must be registered before sale. That guidance does not authenticate a specific online listing or seller.
Primary identity sourceRead the FDA sourceU.S. Food and Drug Administration ↗SAHPRA names Selank among peptide products unlawfully marketed in South Africa and states that products intended to treat, prevent, or alter bodily functions must be registered before sale. That guidance does not authenticate a specific online listing or seller.
Primary identity sourceRead the FDA sourceU.S. Food and Drug Administration ↗SAHPRA names PT-141 among peptide products unlawfully marketed in South Africa and states that products intended to treat, prevent, or alter bodily functions must be registered before sale. That guidance does not authenticate a specific online listing or seller.
Primary identity sourceRead the current DailyMed drug labelNational Library of Medicine, DailyMed ↗SAHPRA names CJC-1295 among peptide products unlawfully marketed in South Africa and states that products intended to treat, prevent, or alter bodily functions must be registered before sale. That guidance does not authenticate a specific online listing or seller.
Primary identity sourceRead the FDA sourceU.S. Food and Drug Administration ↗SAHPRA names CJC-1295 among peptide products unlawfully marketed in South Africa and states that products intended to treat, prevent, or alter bodily functions must be registered before sale. That guidance does not authenticate a specific online listing or seller.
Primary identity sourceRead the FDA sourceU.S. Food and Drug Administration ↗Lilly states that retatrutide is investigational, is not available for public use, and is legally available only through Lilly clinical trials. SAHPRA's public warning identifies products sold under the retatrutide name among falsified or unauthorized GLP-1 agonist products found in the South African market. Neither a seller listing nor a familiar name establishes an authorized product. The exact product record, seller identity, and supply route must be checked through current SAHPRA sources.
Primary identity sourceTRIUMPH-1 Phase 3 study - NCT05929066ClinicalTrials.gov ↗Mazdutide is an investigational clinical program. No seller listing in South Africa can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.
Primary identity sourceGLORY-1 Phase 3 study - NCT05607680ClinicalTrials.gov ↗Ecnoglutide is an investigational clinical program. No seller listing in South Africa can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.
Primary identity sourceSLIMMER Phase 3 study - NCT05813795ClinicalTrials.gov ↗Enicepatide is an investigational clinical program. No seller listing in South Africa can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.
Primary identity sourceCT388-103 Phase 2 study - NCT06525935ClinicalTrials.gov ↗Eloralintide is an investigational clinical program. No seller listing in South Africa can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.
Primary identity sourceEloralintide Phase 2 study - NCT06230523ClinicalTrials.gov ↗Cagrilintide is an investigational clinical program. No seller listing in South Africa can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.
Primary identity sourceREDEFINE 1 Phase 3 study - NCT05567796ClinicalTrials.gov ↗Petrelintide is an investigational clinical program. No seller listing in South Africa can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.
Primary identity sourceZUPREME-1 Phase 2 study - NCT06662539ClinicalTrials.gov ↗Novo Nordisk states that CagriSema was submitted to the US FDA in December 2025 and that an FDA decision is anticipated by late 2026. That US review does not establish South African authorization or supply. SAHPRA's registered-product service is the official route for checking an exact South African product record. No compound-specific South African authorization finding is attached here, so an online offer cannot inherit the sponsor program's identity, evidence, or regulatory status.
Primary identity sourceREDEFINE 1 Phase 3 study - NCT05567796ClinicalTrials.gov ↗MariTide is an investigational clinical program. No seller listing in South Africa can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.
Primary identity sourcePhase 2 dose-ranging study - NCT05669599ClinicalTrials.gov ↗Survodutide is an investigational clinical program. No seller listing in South Africa can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.
Primary identity sourceSYNCHRONIZE-1 Phase 3 study - NCT06066515ClinicalTrials.gov ↗VK2735 is an investigational clinical program. No seller listing in South Africa can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.
Primary identity sourceVENTURE injectable Phase 2 study - NCT06068946ClinicalTrials.gov ↗Pemvidutide is an investigational clinical program. No seller listing in South Africa can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.
Primary identity sourceIMPACT Phase 2b MASH study - NCT05989711ClinicalTrials.gov ↗Amycretin / Zenagamtide is an investigational clinical program. No seller listing in South Africa can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.
Primary identity sourceAMAZE 7 zenagamtide versus semaglutide Phase 3 study - NCT07668414ClinicalTrials.gov ↗Tirzepatide begins here with a US FDA medicine identity. That does not prove the same product, presentation, approval, prescription status, or current availability in South Africa. Verify the exact local records below.
Primary identity sourceCurrent ZEPBOUND prescribing informationNational Library of Medicine, DailyMed ↗Orforglipron / Foundayo begins here with a US FDA medicine identity. That does not prove the same product, presentation, approval, prescription status, or current availability in South Africa. Verify the exact local records below.
Primary identity sourceCurrent FOUNDAYO prescribing informationNational Library of Medicine, DailyMed ↗Semaglutide begins here with a US FDA medicine identity. That does not prove the same product, presentation, approval, prescription status, or current availability in South Africa. Verify the exact local records below.
Primary identity sourceCurrent WEGOVY prescribing informationNational Library of Medicine, DailyMed ↗DSIP / Emideltide is tracked as a US research-market identity, not as an authorization or local supply finding for South Africa. Match the exact category, legal seller identity, and claimed route against the official records on this page.
Primary identity sourceRead the FDA sourceU.S. Food and Drug Administration ↗IGF-1 LR3 is tracked as a US research-market identity, not as an authorization or local supply finding for South Africa. Match the exact category, legal seller identity, and claimed route against the official records on this page.
Primary identity sourceRead the PubChem substance recordNational Library of Medicine, PubChem ↗Kisspeptin-10 / KP-10 is tracked as a US research-market identity, not as an authorization or local supply finding for South Africa. Match the exact category, legal seller identity, and claimed route against the official records on this page.
Primary identity sourceRead the PubChem compound recordNational Library of Medicine, PubChem ↗Melanotan I is tracked as a US research-market identity, not as an authorization or local supply finding for South Africa. Match the exact category, legal seller identity, and claimed route against the official records on this page.
Primary identity sourceRead the current SCENESSE labelNational Library of Medicine, DailyMed ↗NAD+ is tracked as a US research-market identity, not as an authorization or local supply finding for South Africa. Match the exact category, legal seller identity, and claimed route against the official records on this page.
Primary identity sourceRead the PubChem compound recordNational Library of Medicine, PubChem ↗Sermorelin is tracked as a US research-market identity, not as an authorization or local supply finding for South Africa. Match the exact category, legal seller identity, and claimed route against the official records on this page.
Primary identity sourceRead the FDA orphan-drug recordU.S. Food and Drug Administration ↗Thymosin Alpha-1 is tracked as a US research-market identity, not as an authorization or local supply finding for South Africa. Match the exact category, legal seller identity, and claimed route against the official records on this page.
Primary identity sourceRead the FDA sourceU.S. Food and Drug Administration ↗EGRIFTA WR begins here with a US FDA medicine identity. That does not prove the same product, presentation, approval, prescription status, or current availability in South Africa. Verify the exact local records below.
Primary identity sourceCurrent EGRIFTA WR prescribing informationNational Library of Medicine, DailyMed ↗Liraglutide begins here with a US FDA medicine identity. That does not prove the same product, presentation, approval, prescription status, or current availability in South Africa. Verify the exact local records below.
Primary identity sourceCurrent SAXENDA prescribing informationNational Library of Medicine, DailyMed ↗SCENESSE begins here with a US FDA medicine identity. That does not prove the same product, presentation, approval, prescription status, or current availability in South Africa. Verify the exact local records below.
Primary identity sourceCurrent SCENESSE prescribing informationNational Library of Medicine, DailyMed ↗VYLEESI begins here with a US FDA medicine identity. That does not prove the same product, presentation, approval, prescription status, or current availability in South Africa. Verify the exact local records below.
Primary identity sourceCurrent VYLEESI prescribing informationNational Library of Medicine, DailyMed ↗Peptide Local will not manufacture a ranking from thin data. A local table appears only after seller category, authorization or research status, delivery market, price, and source date can all be stated clearly.
Official sources are linked directly. Open them to confirm the current record; this page is a guide, not a substitute for the regulator.